Physician profile
Lashanda Moore
NPI 1205306891
$1,224.14
in general payments reported to CMS, 2019-2025
14 companies · $812 in 2025
The $812 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.14 · 2024: $313 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $315.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $238.21 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $99.96 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $78.70 | 2024-2025 | |
| Shield Therapeutics INC | $75.18 | 2024-2025 | |
| Astellas Pharma US INC | $74.65 | 2025 | Veozah |
| Dexcom, INC. | $62.30 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.71 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.79 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $52.00 | 2024-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $50.58 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $27.98 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.46 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $15.87 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lashanda Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.